glitazones

glitazones

Thiazolidinedione derivative drugs used to treat type II (non-insulin-dependent) diabetes mellitus. Glitazones act by altering fatty acid metabolism by way of peroxisome proliferator-activated receptors which, in effect, increase cell sensitivity to insulin.

thiazolidinediones

; TZD; glitazones oral agents reducing peripheral insulin resistance; used as part of glycaemic control in patients with diabetes mellitus; e.g. pioglitazone, rosiglitazone; may be used in conjunction with metformin (but tend to hypoglycaemia if used with sulphonylurea); there is a reported increased incidence of fractures of small bones in postmenopausal women using TZD
References in periodicals archive ?
Early detection of insulin resistance could allow clinicians to recommend lifestyle changes (such as diet and exercise) or to treat people with antidiabetes drugs called glitazones.
THROUGH 2018 (CASES IN MILLIONS) 44 CURRENT TREATMENT OF DIABETES 44 TYPE 1 DIABETES 44 Insulin 44 Insulin Administration Devices 45 TYPE 2 DIABETES 45 Sulfonylureas 45 TABLE 14 SULFONYLUREAS 46 Biguanides 46 Alpha-Glucosidase Inhibitor 46 Glitazones 47 Prandial Glucose Regulators 47 GLP-1 Analogs/Incretin Mimetics 47 Amylin Mimetic 47 TABLE 15 ORAL HYPOGYCEMICS 48 MONITORING DEVICES FOR DIABETES 48 DIABETES THERAPY MARKET LEADERS 49 DIABETES MARKET ANALYSIS 49 TABLE 16 PROJECTED U.
Cardiovascular risk and cardiometabolic protection: role of glitazones.
Diabetes medications included sulfonylureas (43%), insulin (32%), repaglinide (11%), metformin (66%), acarbose (2%), and glitazones (5%).
PPAR[gamma] agonists, such as the glitazones, increase insulin sensitivity and decrease plasma glucose levels in patients with diabetes, suggesting that these mechanisms could be targets for treatments.
Nonetheless, these results raise the possibility that C droserifolia or some of its components may act, at least in part, as do glitazones and in as powerful a manner as the rosiglitazone positive control.
They also discuss other drug classes in development and clinical trials, including the sodium-glucose cotransporter-2 inhibitors and other pipeline products; compare these therapies to traditional ones like sulphonyureas, glitazones, and insulin; and address the epidemiology and pathogenesis of type 2 diabetes, the role of bariatrics in management, and the organization of care with a community focus.
Glitazones (pioglitazone), used in the treatment of type 2 diabetes, act via a nuclear receptor to induce synthesis of an array of proteins that alter insulin signalling pathways.
There are also concerns about the use of glitazones in this group.
Glitazones - Pioglitizone and Rosiglitazone - a relatively new entry in the world of diabetes was introduced with many tall claims.
These drugs are glitazones, which target insulin resistance, and incretins, which improve insulin production.